Correction to: “Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline” - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction to: “Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline”

  • November 28, 2025

Share

Objective:

To inform about the correction regarding the retirement of the clinical practice guideline for managing menopausal symptoms.

Key Findings:
  • The guideline was deemed no longer relevant to clinical practice.
  • Important inaccuracies or omissions were identified that could lead to substandard patient care.
  • The guideline has been replaced by a more recent publication.
  • The retirement was necessary to prevent potential harm to patients.
Interpretation:

The retirement of the guideline underscores the importance of maintaining current and accurate clinical practices.

Limitations:
  • No specific details on the inaccuracies or omissions were provided.
  • The context does not mention the new guidelines that replace the retired one.
  • Lack of information on the implications of the retirement for current clinical practice.
Conclusion:

The retirement of the guideline highlights the need for continuous updates in clinical practice guidelines to ensure patient safety and care quality.

Original Source(s)

Correction to: “Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline”

  • November 28, 2025

Related Content

Medical Oddities: Dogs share our mortality markers

The bond with dogs runs deeper, the brain enjoys a good sweat, love on screen gets real, and tea carries a little more weight.

Vaginal DNA Assay Shows Promise

A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.

Using a Composite Summary of Daily Sex Hormones to Gauge Time Until Menopause: A Focus on Pregnanediol Glucuronide (PDG)